CP-086 Treatment of chronic hepatitis c with direct action antivirals. Preliminary results

Autor:	L Mallart, M Perpinya, D Malla, E De Puig
Rok vydání:	2016
Předmět:	Ledipasvir Simeprevir medicine.medical_specialty Dasabuvir Sofosbuvir business.industry Ombitasvir chemistry.chemical_compound chemistry Paritaprevir Internal medicine Immunology medicine Ritonavir General Pharmacology Toxicology and Pharmaceutics business Viral load medicine.drug
Zdroj:	European Journal of Hospital Pharmacy. 23:A37.3-A38
ISSN:	2047-9964 2047-9956
DOI:	10.1136/ejhpharm-2016-000875.86
Popis:	Background Marketing of different families of direct acting antivirals (DAAS) for hepatitis C virus (HCV) treatment has transformed the disease course, with high functional cure rates, increasing drug combinations in different clinical situations and virus genotypes. The aim was to describe the population infected by HCV receiving treatment with DAAs and to compare the decrease in viral load (VL) with that reported in clinical trials. Purpose To compare the results obtained in regular clinical practice against the effectiveness results reported in clinical trials for the treatment of chronic hepatitis C (CHC) with DAAs. Material and methods Retrospective observational study from February to August 2015 of all CHC patients on DAA treatment. Variables included: demographics, HIV coinfection, genotype and initial viral load at week 4, week 12 and 12 weeks after treatment completion in patients who had achieved liver fibrosis stage (F). Data were obtained from the pharmacy department database, electronic medical records and drug therapy follow-up. Results 40 patients with CHC received DAA treatment, 68% (27) men, mean age 55.5 years (42–70); 9 (23%) HIV coinfected. Hepatitis virus genotypes were: 1b, 16 (40.0%); 1a, 4 (32.5%); genotype 4, 6 (15%); genotype 4, 3 (10%); and genotype 2, 1 (2.5%). Liver fibrosis stage: F1, 2 (5%), F2, 11 (27.5%), F3, 6 (15%) and F4, 21 (52%), 11 patients had been previously treated. 23 (57.7%) had received ledipasvir/sofosbuvir with or without ribavirin, 7 (17.5%) simeprevir/sofosbuvir and 4 (10.0%) dasabuvir+ombitasvir/paritaprevir/ritonavir; the remaining patients received other drug combinations. At week 4 of treatment, 27 (67.5%) had undetectable VL, 8 (20%) VL Conclusion The percentage of patients with undetectable VL at week 4 was lower than that reported in clinical trials. At week 12, all patients who had completed treatment had undetectable VL, with results comparable with those found in clinical trials. No conflict of interest.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::43fd854a8445c62d48734e3c3ea9bed4 https://doi.org/10.1136/ejhpharm-2016-000875.86 Zobrazit plný text záznamu